Clinical trials: Tick-borne Encephalitis
Tick-borne Encephalitis (TBE)
TBE Seropersistence up to 10 Years After First Booster in Adults
The purpose of this study is to evaluate TBE antibody persistence from 7 to 10 years after the first booster TBE vaccination with FSME-IMMUN 0.5ml.
- Trial name
- NCT01582698
- Testing
- FSME-IMMUN 0.5 ml
- Where
- 2 sites in Poland
- Volunteers
- 243 people, healthy volunteers welcome
- Sponsor
- Pfizer
Tick Borne Encephalitis
Application of a TBE-Vaccine in Obese Persons
Obese people have an altered immune responsiveness. The present study investigates whether this influences immune responses to booster vaccinations (i. e.
- Trial name
- NCT04017052
- Testing
- FSME-IMMUN Vaccine
- Where
- Austria
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Tick Borne Encephalitis, Lyme Disease
Tick-borne Encephalitis and Possible Borrelial Serology
In Europe, tick-borne encephalitis (TBE) virus causing TBE is transmitted by the bite of Ixodes ricinus tick, which can also transmit Lyme borreliae , the causative agent of Lyme borreliosis (LB).
- Trial name
- NCT03958058
- Testing
- Anti-borrelial antibiotic therapy, No antibiotic.
- Where
- Slovenia
- Volunteers
- 690 people
- Sponsor
- University Medical Centre Ljubljana
Encephalitis, Tick-Borne
Tick-Borne Encephalitis (TBE) Seropersistence After First Booster and Response to a Second Booster in Children, Adolescents and Young Adults (Follow-Up to Study 700401)
The main purpose of this study is to assess the seropersistence of TBE virus antibodies in children, adolescents and young adults who received the first booster vaccination with either FSME-IMMUN 0.25 mL Junior or FSME-IMMUN 0.5…
- Trial name
- NCT00894686
- Testing
- FSME-IMMUN 0.25 mL Junior (1.2 µg TBE antigen/0.25 mL) or FSME-IMMUN 0.5 mL (2.4µg TBE antigen/0.5 mL)
- Where
- 4 sites in Austria, Germany and 1 more
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- Pfizer
Tick-borne Encephalitis
Tick-borne Encephalitis and Positive Borrelial Antibodies
In Slovenia, tick-borne encephalitis and Lyme borreliosis are both endemic diseases with high incidence rates and they are both transmitted by a bite of infected Ixodes ricinus tick.
- Trial name
- TBE-LB2014 (NCT02463942)
- Testing
- Doxycycline, Symptomatic therapy, Questionnaire
- Where
- Slovenia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University Medical Centre Ljubljana
Tick-Borne Encephalitis
Cervicovaginal Immune Responses to 3 Deltoid or Thigh Intramuscular (IM) TicoVac
Many viral infections of global importance, including HIV, are transmitted across the mucosal surface of the genital tract. As immunity against these infections is likely to be primarily mediated by antibodies in mucosal…
- Trial name
- CRC306 (NCT01710189)
- Testing
- TicoVac
- Where
- United Kingdom
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Surrey
Tick-Borne Encephalitis, Encephalitis, Tick-Borne
Vaccine Study for Tick-Borne Encephalitis Virus (TBEV)
This was an open label trial of a non-US licensed vaccine for tick-borne encephalitis. The vaccine was licensed by Baxter, and now following an acquisition by Pfizer Inc in Vienna, Austria since 2001, and has an extensive safety…
- Conditions
- Tick-Borne Encephalitis, Encephalitis, Tick-Borne, Tick-Borne Disease, Glycoprotein E, Flavivirus
- Trial name
- TBEV (NCT01031537)
- Testing
- FSME-IMMUN 0.5ml Baxter
- Where
- 2 sites in United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Aseptic Meningitis
Aseptic Meningoencephalitis in Slovenia
The main objective of this study is: to establish etiology of acute aseptic meningitis/meningoencephalitis in Slovenia to assess the clinical course and outcome of tick-borne encephalitis and Lyme neuroborreliosis to characterize…
- Trial name
- NCT02328469
- Testing
- symptomatic therapy, Ceftriaxone or Doxycycline, questionnaire
- Where
- 2 sites in Slovenia
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- University Medical Centre Ljubljana
Tick-borne Encephalitis
Humoral Response to Tick-borne Encephalitis Vaccine in Elderly
Antibody titers after tick-borne encephalitis (TBE) vaccination are less in elderly and vaccination breakthroughs are more common in this age group.
- Trial name
- NCT01361776
- Testing
- FSME-immune
- Where
- 6 sites in Finland, Sweden
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Sormland County Council, Sweden
Encephalitis, Tick-borne
Safety and Immunogenicity Study of 3 Vaccinations With TICOVAC in 2 Dosages in Healthy Children Aged Between 6 Months and 3 Years
The purpose of this study is to evaluate a) whether the seroconversion rates in children are equivalent after two and/or three partial vaccinations with TICOVAC 0.25 mL and TICOVAC 0.5 mL, and b) whether there is a difference in…
- Trial name
- NCT00161746
- Testing
- Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
- Where
- 7 sites in Austria
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pfizer
Tick-borne Encephalitis
Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 1 to 6 Years.
The purpose of this study is to investigate the safety and immunogenicity of three different concentrations of a TBE vaccine in healthy children aged 1 to 6 years.
- Trial name
- NCT00161772
- Testing
- Tick-borne Encephalitis Vaccine
- Where
- 23 sites in Austria, Germany
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pfizer
Tick-borne Encephalitis
Investigation of the Seropersistence of TBE Antibodies and the Booster Response to FSME-IMMUN 0.5 ml in Adults Aged 18 - 67 Years
The purpose of this study is to assess: TBE antibody persistence 2 and 3 years after the third TBE vaccination with FSME-IMMUN 0.5ml by means of ELISA and neutralization test (NT).
- Trial name
- NCT00161785
- Testing
- FSME-IMMUN 0.5ml
- Where
- 2 sites in Poland
- Volunteers
- 340 people, healthy volunteers welcome
- Sponsor
- Pfizer
Tick-borne Encephalitis
Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 6 to 16 Years.
The purpose of this study is to investigate the safety and immunogenicity of three different concentrations of a TBE vaccine will be investigated in healthy children aged 6 to 16 years.
- Trial name
- NCT00161798
- Testing
- Tick-borne encephalitis vaccine
- Where
- 23 sites in Germany
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pfizer
Encephalitis, Tick-borne
Safety Study in Volunteers From 16 to 65 Years of Age: FSME IMMUN NEW vs. ENCEPUR
The purpose of this study is to assess the safety of a vaccination schedule consisting of two vaccinations (21-35 days apart) with the tick-borne encephalitis (TBE) vaccine FSME-IMMUN NEW (5 consecutive lots) in comparison to…
- Trial name
- NCT00161824
- Testing
- Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
- Where
- 7 sites in Poland
- Volunteers
- 3,800 people, healthy volunteers welcome
- Sponsor
- Pfizer
Encephalitis, Tick-borne
FSME IMMUN NEW Follow-up to Study 199 in Children Aged 1 to 6 Years
The purpose of this study is to investigate the safety and immunogenicity of the third vaccination with one of three different concentrations of a TBE vaccine in all subjects who completed two vaccinations in one of the three…
- Trial name
- NCT00161850
- Testing
- Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
- Where
- 25 sites in Austria, Germany
- Volunteers
- 615 people, healthy volunteers welcome
- Sponsor
- Pfizer
Tick-borne Encephalitis
Safety Study of FSME-IMMUN NEW in Healthy Children and Adolescents Aged 1 to 15 Years
The purpose of this study is to investigate the safety of five consecutive lots of FSME-IMMUN NEW in healthy volunteers. The main criterion for investigation is the fever rate after the first vaccination in three different age…
- Trial name
- NCT00161863
- Testing
- FSME-IMMUN NEW 0.25 ml
- Where
- 8 sites in Austria, Germany and 1 more
- Sponsor
- Pfizer
Encephalitis, Tick-borne
FSME IMMUN NEW Follow-up to Study 208 in Volunteers Aged 16 to 66 Years
The aim of this study is to evaluate the safety of the third vaccination with FSME-IMMUN NEW in all volunteers who received both vaccinations in Baxter study 208 (safety study of FSME IMMUN NEW and ENCEPUR in healthy volunteers…
- Trial name
- NCT00161876
- Testing
- Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
- Where
- 8 sites in Poland
- Volunteers
- 3,973 people, healthy volunteers welcome
- Sponsor
- Pfizer
Encephalitis, Tick-borne
FSME IMMUN NEW Follow-up to Study 205 in Children Aged 6 to 16 Years
The purpose of this study is to investigate the safety and immunogenicity of the third vaccination with one of three different concentrations of a TBE vaccine in all volunteers who completed two vaccinations in one of the three…
- Trial name
- NCT00161889
- Testing
- Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
- Where
- 19 sites in Germany
- Volunteers
- 615 people, healthy volunteers welcome
- Sponsor
- Pfizer
Encephalitis, Tick-borne
Immunogenicity and Safety Study of a Rapid Immunization Schedule With FSME-IMMUN 0.5 mL in Healthy Adults Aged 16 - 65 Years
The objective of this study is to establish the earliest time point at which vaccines are expected to show seropositive antibody levels after vaccination with FSME-IMMUN 0.5 mL using a rapid immunization schedule (2 vaccinations…
- Trial name
- NCT00161954
- Testing
- Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
- Where
- Belgium
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pfizer
Encephalitis, Tick-Borne
TBE Antibody Persistence and Booster Vaccination Study in Children and Adolescents (Follow-up to Study 209)
The purpose of this study is to assess the seropersistence of TBE antibodies in children and adolescents aged 1 to 15 years at the time of their first vaccination, 24 months and 34 months after completion of primary immunization…
- Trial name
- NCT00161967
- Testing
- Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
- Where
- 3 sites in Austria, Germany and 1 more
- Volunteers
- 375 people, healthy volunteers welcome
- Sponsor
- Pfizer